This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

James D. Cherry, MD; Edward A. Mortimer, Jr, MD

JAMA. 1987;257(10):1375-1376.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The report of the Public Health Service's Interagency Group to Monitor Vaccine Development, Production, and Usage published in this issue of THE JOURNAL¹ as well as the recent (Sept 22 to 24,1986) workshop on acellular pertussis vaccines in Bethesda, Md, sponsored by the same group, have provided valuable information about Japanese acellular pertussis vaccines. Using the data presented in the government report and at that workshop as well as in recent US studies^2-4 of a diphtheria and tetanus toxoids and pertussis vaccine (DTP) with a Japanese acellular pertussis component, we will review what could be expected if acellular pertussis vaccines were to replace whole-cell vaccines in the United States.

The available data indicate that fever (both in frequency and degree) and other common systemic reactions such as fretfulness, anorexia, vomiting, and drowsiness will be less common with the use of acellular pertussis vaccines. Although local reactions of some . . . [Full Text PDF of this Article]

Author Affiliations
UCLA School of Medicine Los Angeles; Case Western Reserve University School of Medicine Cleveland

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?